Share:

Anna Ridderstad Wollberg

Senior projektledare

Tel

+46 10 516 60 61

Email

anna.ridderstad.wollberg@ri.se

Location

Stockholm

Ask me about

Posts

Ask me about

NucleoDry – exploring the opportunities with dry vaccines

RISE, KI, NorthXBiologics and Vecura formed this consortium with the aim to building a national infrastructure around gene therapies through exploring the possibilities of dry vaccines.

Vaccine

Vaccine development is a prioritised area to increase global health. At RISE, we offer infrastructure and broad expertise in the field of vaccines. We can guide you through the entire process, from research and regulatory requirem…

Vaccin and non-cliical safety

RISE can help with the design and execution of the non-clinical safety testing for vaccine from characterisation through formulation and safety studies to the approval by regulatory agencies. Toxicologists and immunologists can pl…

Toxicological tests and safety

We can test and assess the potential toxicities/hazards of emerging drug candidates, industrial chemicals, food additives and medical devices, contributing to safety assessments required for market approvals. We can also support i…

In vitro methods for toxicology

Our wide selection of in vitro models help you confirm and optimise pharmacological effects, to predict and analyse toxic effects and to study ADME properties of drugs in different phases of development. Toxicological assessment o…

Pharmaceutical Development

At RISE we know the entire pharmaceutical development chain, from target to patient. We can help with process development, analysis (GMP/GLP), formulation and production (GMP) of the pharmaceutical product for clinical trials, but…

Posts